Doxycycline Reduces Mortality and Injury to the Brain and Cochlea in Experimental Pneumococcal Meningitis

Overview

Journal Infect Immun

Publisher American Society for Microbiology

Specialty Allergy & Immunology

Date 2006 Jun 23

PMID 16790761

Citations 29

Authors

Damian N Meli

Roney S Coimbra

Dominik G Erhart

Gerard Loquet

Caroline L Bellac

Martin G Tauber

Ulf Neumann

Stephen L Leib

Affiliations

Soon will be listed here.

Abstract

Bacterial meningitis is characterized by an inflammatory reaction to the invading pathogens that can ultimately lead to sensorineural hearing loss, permanent brain injury, or death. The matrix metalloproteinases (MMPs) and tumor necrosis factor alpha-converting enzyme (TACE) are key mediators that promote inflammation, blood-brain barrier disruption, and brain injury in bacterial meningitis. Doxycycline is a clinically used antibiotic with anti-inflammatory effects that lead to reduced cytokine release and the inhibition of MMPs. Here, doxycycline inhibited TACE with a 50% inhibitory dose of 74 microM in vitro and reduced the amount of tumor necrosis factor alpha released into the cerebrospinal fluid by 90% in vivo. In an infant rat model of pneumococcal meningitis, a single dose of doxycycline (30 mg/kg) given as adjuvant therapy in addition to ceftriaxone 18 h after infection significantly reduced the mortality, the blood-brain barrier disruption, and the extent of cortical brain injury. Adjuvant doxycycline (30 mg/kg given subcutaneously once daily for 4 days) also attenuated hearing loss, as assessed by auditory brainstem response audiometry, and neuronal death in the cochlear spiral ganglion at 3 weeks after infection. Thus, doxycycline, probably as a result of its anti-inflammatory properties, had broad beneficial effects in the brain and the cochlea and improved survival in this model of pneumococcal meningitis in infant rats.

Citing Articles

Adjunctive treatments for pneumococcal meningitis: a systematic review of experimental animal models.

Koning R, van Roon M, Brouwer M, van de Beek D Brain Commun. 2024; 6(3):fcae131.

PMID: 38707710 PMC: 11069119. DOI: 10.1093/braincomms/fcae131.

Doxycycline cotherapy with albendazole relieves neural function damage in C57BL/6 and BALB/c mice infected with Angiostrongylus cantonensis.

Sofiyatun E, Chen K, Chou C, Lee H, Day Y, Chiang P Biomed J. 2024; 48(1):100727.

PMID: 38636898 PMC: 11751418. DOI: 10.1016/j.bj.2024.100727.

Central Nervous System Antimicrobial Exposure and Proposed Dosing for Anthrax Meningitis.

Bradley J, Bulitta J, Cook R, Yu P, Iwamoto C, Hesse E Clin Infect Dis. 2024; 78(6):1451-1457.

PMID: 38412060 PMC: 11175673. DOI: 10.1093/cid/ciae093.

The CCR5 antagonist maraviroc exerts limited neuroprotection without improving neurofunctional outcome in experimental pneumococcal meningitis.

Le N, Steinfort M, Grandgirard D, Maleska A, Leppert D, Kuhle J Sci Rep. 2022; 12(1):12945.

PMID: 35902720 PMC: 9334283. DOI: 10.1038/s41598-022-17282-0.

Doxycycline prevents blood-brain barrier dysfunction and microvascular hyperpermeability after traumatic brain injury.

Robinson B, Isbell C, Melge A, Lomas A, Anasooya Shaji C, Mohan C Sci Rep. 2022; 12(1):5415.

PMID: 35354869 PMC: 8967830. DOI: 10.1038/s41598-022-09394-4.

References

Leib S, Leppert D, Clements J, Tauber M . Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis. Infect Immun. 2000; 68(2):615-20. PMC: 97183. DOI: 10.1128/IAI.68.2.615-620.2000. View

Miller J, Chi D, OKeeffe L, Kruszka P, Raphael Y, Altschuler R . Neurotrophins can enhance spiral ganglion cell survival after inner hair cell loss. Int J Dev Neurosci. 1997; 15(4-5):631-43. DOI: 10.1016/s0736-5748(96)00117-7. View

Oostenbrink R, Maas M, Moons K, Moll H . Sequelae after bacterial meningitis in childhood. Scand J Infect Dis. 2002; 34(5):379-82. DOI: 10.1080/00365540110080179. View

Nau R, Soto A, Bruck W . Apoptosis of neurons in the dentate gyrus in humans suffering from bacterial meningitis. J Neuropathol Exp Neurol. 1999; 58(3):265-74. DOI: 10.1097/00005072-199903000-00006. View

Cho Y, Gong T, Stover T, Lomax M, Altschuler R . Gene expression profiles of the rat cochlea, cochlear nucleus, and inferior colliculus. J Assoc Res Otolaryngol. 2002; 3(1):54-67. PMC: 3202363. DOI: 10.1007/s101620010042. View

Winter A, Comis S, Osborne M, Tarlow M, Stephen J, Andrew P . A role for pneumolysin but not neuraminidase in the hearing loss and cochlear damage induced by experimental pneumococcal meningitis in guinea pigs. Infect Immun. 1997; 65(11):4411-8. PMC: 175634. DOI: 10.1128/iai.65.11.4411-4418.1997. View

Whittaker M, Floyd C, Brown P, Gearing A . Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev. 2001; 99(9):2735-76. DOI: 10.1021/cr9804543. View

Roach D, Fitridge R, Laws P, Millard S, Varelias A, Cowled P . Up-regulation of MMP-2 and MMP-9 leads to degradation of type IV collagen during skeletal muscle reperfusion injury; protection by the MMP inhibitor, doxycycline. Eur J Vasc Endovasc Surg. 2002; 23(3):260-9. DOI: 10.1053/ejvs.2002.1598. View

LEPPER M, DOWLING H . Treatment of pneumococcic meningitis with penicillin compared with penicillin plus aureomycin; studies including observations on an apparent antagonism between penicillin and aureomycin. AMA Arch Intern Med. 1951; 88(4):489-94. DOI: 10.1001/archinte.1951.03810100073006. View

10.

Shinohara T, Bredberg G, Ulfendahl M, Pyykko I, Olivius N, Kaksonen R . Neurotrophic factor intervention restores auditory function in deafened animals. Proc Natl Acad Sci U S A. 2002; 99(3):1657-60. PMC: 122246. DOI: 10.1073/pnas.032677999. View

11.

Pasquale T, Tan J . Nonantimicrobial effects of antibacterial agents. Clin Infect Dis. 2004; 40(1):127-35. DOI: 10.1086/426545. View

12.

Klein M, Koedel U, Pfister H, Kastenbauer S . Morphological correlates of acute and permanent hearing loss during experimental pneumococcal meningitis. Brain Pathol. 2003; 13(2):123-32. PMC: 8095810. DOI: 10.1111/j.1750-3639.2003.tb00012.x. View

13.

Comis S, Osborne M, Stephen J, Tarlow M, Hayward T, Mitchell T . Cytotoxic effects on hair cells of guinea pig cochlea produced by pneumolysin, the thiol activated toxin of Streptococcus pneumoniae. Acta Otolaryngol. 1993; 113(2):152-9. DOI: 10.3109/00016489309135784. View

14.

Lee C, Xu B, Hashimoto T, McCulloch C, Yang G, Young W . Doxycycline suppresses cerebral matrix metalloproteinase-9 and angiogenesis induced by focal hyperstimulation of vascular endothelial growth factor in a mouse model. Stroke. 2004; 35(7):1715-9. DOI: 10.1161/01.STR.0000129334.05181.b6. View

15.

Hurewitz A, Wu C, Mancuso P, Zucker S . Tetracycline and doxycycline inhibit pleural fluid metalloproteinases. A possible mechanism for chemical pleurodesis. Chest. 1993; 103(4):1113-7. DOI: 10.1378/chest.103.4.1113. View

16.

Leib S, Clements J, Lindberg R, Heimgartner C, Loeffler J, Pfister L . Inhibition of matrix metalloproteinases and tumour necrosis factor alpha converting enzyme as adjuvant therapy in pneumococcal meningitis. Brain. 2001; 124(Pt 9):1734-42. DOI: 10.1093/brain/124.9.1734. View

17.

Dichgans M, Jager L, Mayer T, Schorn K, Pfister H . Bacterial meningitis in adults: demonstration of inner ear involvement using high-resolution MRI. Neurology. 1999; 52(5):1003-9. DOI: 10.1212/wnl.52.5.1003. View

18.

Suomalainen K, Sorsa T, Golub L, Ramamurthy N, Lee H, Uitto V . Specificity of the anticollagenase action of tetracyclines: relevance to their anti-inflammatory potential. Antimicrob Agents Chemother. 1992; 36(1):227-9. PMC: 189275. DOI: 10.1128/AAC.36.1.227. View

19.

Yim C, Flynn N, Fitzgerald F . Penetration of oral doxycycline into the cerebrospinal fluid of patients with latent or neurosyphilis. Antimicrob Agents Chemother. 1985; 28(2):347-8. PMC: 180244. DOI: 10.1128/AAC.28.2.347. View

20.

Paul R, Lorenzl S, Koedel U, Sporer B, Vogel U, Frosch M . Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis. Ann Neurol. 1998; 44(4):592-600. DOI: 10.1002/ana.410440404. View